ASCO 2024: Precede Biosciences assay classifies HER2 and ER status in cancers
Precede Bio’s liquid biopsy assay could help to guide treatment options for patients with HER2 or ER+ cancers.
Precede Bio’s liquid biopsy assay could help to guide treatment options for patients with HER2 or ER+ cancers.
The device had a success rate of 95%, with 83% of the participants finding the procedure comparable to or less painful than manual blood draws.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
IR-MED’s PressureSafe device cuts pressure injury incidence by half
AiM Medical Robotics partners with Harvard Hospital for DBS study
HeartBeam’s AI device outperforms experts in detecting atrial flutter
UK clinical trials industry tackles recent changes in the sector